Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,469 across all filing types
Latest filing 2025-10-13 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - ASCLETIS SELECTS A BEST-IN-CLASS ONCE-MONTHLY SUBCUTANEOUSLY ADMINISTERED GLP-1R/GIPR DUAL PEPTIDE AGONIST, ASC35, FOR CLINICAL DEVELOPMENT
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement filed on the Hong Kong Stock Exchange regarding the selection of a clinical development candidate (ASC35). It does not present financial results, management changes, dividends, share transactions, or other specific report types. It is a general corporate/regulatory announcement, so it should be classified under the fallback category Regulatory Filings (RNS).
2025-10-13 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 1% confidence The document is a Hong Kong Stock Exchange “Next Day Disclosure Return” (Form FF305) for Ascletis Pharma Inc., detailing changes in issued shares and treasury shares, on-market repurchases, and sale of treasury shares. It is the actual regulatory filing of a share buyback and treasury share sale rather than an announcement of an upcoming report. This matches the “Transaction in Own Shares” category (POS).
2025-10-10 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 1% confidence The document is a Next Day Disclosure Return (Form FF305) filed pursuant to Hong Kong Stock Exchange listing rules, detailing changes in issued and treasury shares, repurchases of shares (treasury holdings), and on-market sale of treasury shares. It is a regulatory report of the company’s transactions in its own shares. This matches the definition for “Transaction in Own Shares” (POS).
2025-10-03 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2025
Regulatory Filings Classification · 1% confidence The document is a Monthly Return (Form FF301) submitted to Hong Kong Exchanges and Clearing Limited under Chapter 19B of the Hong Kong Listing Rules. It details movements in authorised and issued share capital, share options, repurchases, and other capital changes for the month ended 30 September 2025. It is a statutory listing‐rule return rather than an AGM presentation, earnings release, or annual/interim report. As it does not precisely match any more specific category (e.g., a one-off share issue announcement or call transcript) it falls under the fallback category for miscellaneous regulatory filings.
2025-10-03 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 1% confidence The document is HKEX Form FF305 “Next Day Disclosure Return” detailing changes in issued and treasury shares and, in particular, extensive tables of share repurchases (number of shares repurchased, repurchase prices, aggregate amounts) under Main Board Rules and GEM Rules. This is a regulatory disclosure of the company’s own share transactions (repurchases and treasury share movements), fitting the “Transaction in Own Shares” category (Code: POS).
2025-10-02 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2025
Regulatory Filings Classification · 1% confidence The document is the FF301 “Monthly Return for Equity Issuer” filed under Hong Kong Exchange Listing Rules, detailing monthly movements in share capital, issued shares, options and confirmations under Main Board Rule 13.25C/GEM Rule 17.27C. It is not an earnings release, annual/interim report or one‐off share issue announcement but a routine regulatory filing. No more specific category applies, so it is classified under the fallback Regulatory Filings category (RNS).
2025-10-02 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.